Alumis’ (ALMS) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Alumis (NASDAQ:ALMS) in a research report report published on Friday morning,Weiss Ratings reports.

Other research analysts have also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and set a $14.00 price objective on shares of Alumis in a report on Thursday, August 14th. Morgan Stanley cut their target price on shares of Alumis from $23.00 to $22.00 and set an “overweight” rating for the company in a research report on Friday, August 15th. Wells Fargo & Company started coverage on Alumis in a report on Friday, July 25th. They set an “overweight” rating and a $17.00 price target on the stock. Finally, Wall Street Zen raised Alumis from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $20.17.

Alumis Price Performance

Shares of NASDAQ:ALMS opened at $4.51 on Friday. Alumis has a 1 year low of $2.76 and a 1 year high of $13.00. The company has a market cap of $469.31 million, a P/E ratio of -0.96 and a beta of -1.47. The stock’s fifty day moving average price is $4.44 and its 200-day moving average price is $4.23.

Alumis (NASDAQ:ALMS) last issued its earnings results on Wednesday, August 13th. The company reported ($1.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.06). The business had revenue of $2.67 million during the quarter, compared to analyst estimates of $1.80 million. On average, sell-side analysts anticipate that Alumis will post -8.51 earnings per share for the current year.

Hedge Funds Weigh In On Alumis

A number of institutional investors have recently bought and sold shares of ALMS. Rhumbline Advisers lifted its position in Alumis by 21.7% during the first quarter. Rhumbline Advisers now owns 16,543 shares of the company’s stock valued at $102,000 after purchasing an additional 2,949 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Alumis by 37.0% in the first quarter. Bank of New York Mellon Corp now owns 42,403 shares of the company’s stock worth $260,000 after buying an additional 11,453 shares during the period. Towerview LLC lifted its position in shares of Alumis by 3.6% during the 1st quarter. Towerview LLC now owns 430,000 shares of the company’s stock valued at $2,640,000 after buying an additional 15,000 shares in the last quarter. BML Capital Management LLC purchased a new position in shares of Alumis during the 1st quarter valued at about $305,000. Finally, Charles Schwab Investment Management Inc. grew its stake in shares of Alumis by 12.7% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 127,854 shares of the company’s stock valued at $785,000 after acquiring an additional 14,453 shares during the period.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.